Lee Biosolutions at the Forefront of Renin Production

Published: Apr 27th, 2006

July 12, 2006; St. Louis, Missouri - After a 10-year depletion of all known supplies of native human Renin, Lee Biosolutions developed and has geared up production on the marker that's critical in hypertension research, among other illnesses.

According to Lee Biosolutions president, Burton Lee, the company recognized the lack of availability of this important enzyme. "We had the raw materials, human kidneys, needed to produce the native human Renin ," said Lee. "We also had the R & D capabilities to isolate, purify and stabilize the enzyme. We worked hard to perfect the process so that we could begin production and answer the demands of the research community."

Renin is an enzyme derived from human kidneys that plays a crucial role in cardiovascular research , both in terms of diagnostics and pharmaceuticals. This research is resulting in new classes of drugs to manage hypertension. In March 2005, Novartis Pharmaceuticals announced the first daily-dose renin inhibitor to treat hypertension and improve organ protection.

Its potential reach, however, is much wider, and includes Cushing's disease , Addison's disease, and pituitary disease. Without Lee Biosolutions' production of Renin, research would have been hindered as the previous supplies were depleted.

"The research is critical to many health issues we face," said Lee. "Once the Renin was used up, researchers would have been forced to derive their own Renin as they needed it. That takes vital dollars away from the research itself. Our production of Renin allows that money to be spent where it's needed - in developing accurate tests and effective treatments for these serious illnesses."

For over 30 years, Lee Biosolutions has been providing proteins, enzymes and other materials to research facilities around the country that work to advance the healthcare industry. By providing Solutions on Demand, Lee Biosolutions has become the preferred source for materials such as Renin and myeloperoxidase (MPO).

Lee Biosolutions is a leader in the biomaterials industry, providing quality biomaterial products to clinical labs and researchers around the world, developing tomorrows cures. Leebio has provided human proteins used in a number of high profile biomarker studies. For more information or to place an order,contact:

Lee Biosolutions, Inc
2924 Mary Ave
St. Louis, MO 63144
Tel:314-968-1091
www.leebio.com